Golee Dawaai Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 Cr
- Revenue Growth 105.39%
- Profit Growth -89.06%
- Ebitda 48.90%
- Net Worth -13.33%
- Total Assets 15.24%
About Golee Dawaai Pharma
Golee Dawaai Pharma Private Limited (GDPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 July 2021 (Three years and six months 28 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 Cr.
Jyoti Singh and Mahabali Singh serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100MH2021PTC363357
-
Company No.
363357
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Jul 2021
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Golee Dawaai Pharma?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Jyoti Singh | Director | 06-Jul-2021 | Current |
Mahabali Singh | Director | 06-Jul-2021 | Current |
Financial Performance of Golee Dawaai Pharma.
Golee Dawaai Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 105.39% increase. The company also saw a substantial fall in profitability, with a 89.06% decrease in profit. The company's net worth observed a substantial decline by a decrease of 13.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Golee Dawaai Pharma?
Unlock access to Golee Dawaai Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹30.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 3.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
31 Jul 2023 | Others | ₹3.00 Cr | Open |
How Many Employees Work at Golee Dawaai Pharma?
Golee Dawaai Pharma has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Golee Dawaai Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Golee Dawaai Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.